Troriluzole for spinocerebellar ataxia

Troriluzole is in development for the treatment of adults with spinocerebellar ataxia (SCA). SCAs are a group of ataxias (lack of muscular control) which are inherited from parents. SCAs do not usually begin until adulthood and can affect people from the age of 25 up to 80, depending on the type of SCA. The symptoms vary depending on the type of SCA but can include problems with balance and co-ordination, increasingly slurred, slow and unclear speech, difficulty swallowing, muscle stiffness and cramps, loss of sensation in the hands and feet, memory loss, difficulties with spoken language, slow eye movement and reduced bladder control. There is no cure for SCA, and no specific treatments are currently available to slow or stop disease progression. Therefore, there is an unmet need for specific medicinal treatments to support patients with SCA.